FEBS Open BioCancer BiologyPeer-reviewed journal article
Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell lines
Tharsagini V. NanthaprakashiD, Campbell W. GourlayiD, Ina OehmeiD, Michelle Dawn GarrettiD, Jindrich Cínatl, Mark N. WassiD, Martin MichaelisiD
- Citations
- 2
- FWCI
- 1.20
- Field percentile
- top 21%
Abstract
Here, we introduce sublines of the EGFR-mutant non-small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2{micro}M, HCC4006rGEFI1{micro}M), erlotinib (HCC827rERLO2{micro}M, HCC4006rERLO1{micro}M), and afatinib (HCC827rAFA50nM, HCC4006rAFA100nM). All sublines displayed resistance to gefitinib, erlotinib, afatinib, and the third-generation EGFR kinase inhibitor osimertinib that overcomes T790M-mediated resistance. HCC4006rERLO1{micro}M displayed a spindle-like morphology in agreement with previous findings that had detected epithelial-mesenchymal-transition (EMT) in its precursor cell line HCC4006rERLO0.5{micro}M. EMT had also been reported for the HCC4006rGEFI1{micro}M precursor cell line HCC4006rGEFI0.5{micro}M and for HCC4006rAFA100nM, but the morphologies of HCC4006rGEFI1{micro}M or HCC4006rAFA100nM did not support this, suggesting plasticity in EMT regulation during the drug adaptation process and in established resistant cell lines. Accordingly, HCC4006rERLO1{micro}M displayed resistance to MEK and AKT inhibitors in contrast to its precursor HCC4006rERLO0.5{micro}M. We also detected metabolic plasticity, i.e., a temporary Warburg metabolism, in HCC4006 and HCC827rGEFI2{micro}M. Response profiles to cytotoxic anti-cancer drugs, kinase inhibitors, and HDAC inhibitors resulted in complex patterns that were specific for each individual subline without obvious overlaps, indicating individual resistance phenotypes. All resistant sublines remained sensitive or displayed collateral sensitivity to at least one of the investigated drugs. In conclusion, the comparison of EGFR kinase-resistant NSCLC sublines with their precursor cell lines that had been previously characterised at a lower resistance level and metabolic investigations indicated phenotypic plasticity during the resistance formation process and in established cell lines. This plasticity may contribute to the well-known variability in cell line phenotypes observed between different laboratories and in intra-laboratory experiments.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: drug response / drug discovery
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Complementary modes of resistance to EGFR TKI in lung adenocarcinoma through MAPK activation and cellular plasticity
Matthew Zatzman, Àlvaro Quintanal-Villalonga, … Helena Alexandra Yu·bioRxiv·May 7, 2025
- Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axis
Alessandra Morselli, Chiara Miroglio, … Mattia Lauriola·bioRxiv·May 13, 2026
- Selection for targeted therapy resistance leads to an indirect selection for higher phenotypic plasticity and enhanced evolvability to orthogonal stressors
Alicia Bjornberg, Xierali Aobuli, … Andriy Marusyk·bioRxiv·Apr 3, 2026
- Investigating EMT-mediated resistance to EGFR tyrosine kinase inhibitors in NSCLC using innovative organoid models
N. Kobayashi, S. Katakura, … T. Kaneko·bioRxiv·Feb 8, 2024
- Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity
Letian Zhang, Meenalakshmi Chinnam, … David W. Goodrich·bioRxiv·Aug 4, 2025
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
L. Brunet, D. Alexandre, … L. Grumolato·bioRxiv·Jun 19, 2023